Related content

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors

By Hurwitz Herbert   Cohen Roger   McGovren J.   Hirawat Samit   Petros William   Natsumeda Yutaka   Yoshinari Tomoko  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 139-147

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma

By Konstadoulakis Manousos   Antonakis Pantelis   Tsibloulis Basil   Stathopoulos George   Manouras Andreas   Mylonaki Despoina   Golematis Basil  

Cancer Chemotherapy and Pharmacology, Vol. 48, Iss. 5, 2001-11 ,pp. : 417-420

Springer Publishing Company

Access to resources Recommend Favorite

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors

By Plummer Ruth   Madi Ayman   Jeffels Melinda   Richly Heike   Nokay Bahar   Rubin Stephen   Ball Howard   Weller Steve   Botbyl Jeffrey   Gibson Diana   Scheulen Max  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 93-101

Springer Publishing Company

Access to resources Recommend Favorite

Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors

By  

The Oncologist, Vol. 23, Iss. 2, 2018-02 ,pp. : 155-e17

John Wiley & Sons Inc

Access to resources Recommend Favorite

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

By Murakami H.   Kurata T.   Onozawa Y.   Watanabe J.   Ono A.   Takahashi T.   Yamamoto N.   Fujisaka Y.   Kiyota H.   Hayashi H.   Tanaka K.   Nakagawa K.   Kuroda S.  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 623-630

Springer Publishing Company

Access to resources Recommend Favorite